China’s Pharmaceutical Sector Thrives Amid Tech Scrutiny
SHANGHAI, May 26 – The rapid growth of China’s pharmaceutical industry remains steady despite increased scrutiny from Beijing on deals involving sensitive technologies, according to Leo Tian, the CEO of JW Therapeutics.
As global pharmaceutical companies look to cut costs in anticipation of patent expirations, many are keenly interested in experimental medicines developed in China. Industry experts are predicting that biotech licensing agreements could hit new heights this year.
However, the situation is complicated. Recently, China ordered the U.S. tech company Meta to dismantle its acquisition of AI startup Manus, valued at over $2 billion. This move highlights Beijing’s tightening grip on U.S. investments in domestic firms that are working on advanced technologies, creating uncertainty across various sectors.
Tian reassured that business continues as usual for JW Therapeutics. “Our partnerships, especially in cell and gene therapies, rely heavily on international collaboration. So far, I haven’t noticed any disruption,” he stated.
JW Therapeutics, with significant backing from U.S. drugmaker Bristol Myers Squibb through its subsidiary Juno Therapeutics, focuses on developing cell immunotherapy products. Tian also mentioned that the company is actively seeking international collaboration for its pipeline projects.
The recent developments regarding Meta’s acquisition signal rising caution among global investors eyeing advanced tech firms linked to China.
(Reporting by Andrew Silver; Edited by Gus Trompiz)
